
CALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
- | - | - | - | 0.00 | 280.00 | -33.33 | 0.6 | 1.94 | 2200 | 115500 |
- | - | - | - | 0.00 | 285.00 | -12.50 | 1.05 | -3.85 | -1100 | 27500 |
- | - | - | - | 0.00 | 290.00 | -16.67 | 1 | 0.0 | 0 | 22000 |
1100 | 0 | 0.00 | 48.65 | 0.00 | 295.00 | -33.33 | 1 | -25.0 | -2200 | 6600 |
12100 | 0 | 0.00 | 38.55 | 0.00 | 300.00 | -11.11 | 1.6 | -4.43 | -17600 | 379500 |
- | - | - | - | 0.00 | 305.00 | 4.08 | 2.55 | -2.5 | -1100 | 42900 |
11000 | - | 0.00 | 23.3 | 0.00 | 310.00 | 23.21 | 3.45 | 2.41 | 2200 | 93500 |
3300 | 2200 | 200.00 | 20.9 | 200.00 | 315.00 | 50.00 | 5.7 | 6.67 | 1100 | 17600 |
13200 | 3300 | 33.33 | 18.8 | 33.33 | 320.00 | 22.83 | 5.65 | 12.68 | 19800 | 176000 |
19800 | 0 | 0.00 | 15.45 | 0.00 | 325.00 | 36.04 | 7.55 | -7.32 | -3300 | 41800 |
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, c... Read More
sector: Pharmaceuticals
as on 2/3/2023 3:59:28 PM
₹ 331.4 -7.60 -2.24PROMOTER - TOTAL27.20%
Indian: 27.20%
Foreign: 0%
NON-PROMOTER - TOTAL 72.80%
Institutions: 31.41%
Non-Institutions: 41.39%
CUSTODIES - 0.00%
Custodies: 0.00%
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
Decline in Molnupiravir sales to impact performance
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
No Data Available To Display Chart
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,027.65 | 95.06 | 2,46,567.66 | 486.73 | 0.97 | 4,549.90 | 108.48 |
Cipla Ltd | 1,026.00 | 29.84 | 82,570.82 | 678.52 | 0.49 | 3,541.16 | 291.76 |
Divis Laboratories Ltd | 2,884.45 | 25.79 | 76,573.08 | 486.85 | 1.04 | 1,823.38 | 454.85 |
Dr Reddys Laboratories Ltd | 4,358.40 | 30.75 | 72,569.42 | 324.60 | 0.69 | 3,879.60 | 1,156.24 |
Torrent Pharmaceuticals Ltd | 1,545.00 | 49.44 | 51,856.61 | 229.00 | 1.57 | 1,826.00 | 191.38 |
Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The companys strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture and sale of APIs and... Read More
Reports by Laurus Labs Ltd
Reports by Laurus Labs Ltd